Literature DB >> 8251805

Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection.

L T Mimms1, J W Mosley, F B Hollinger, R D Aach, C E Stevens, M Cunningham, D V Vallari, L H Barbosa, G J Nemo.   

Abstract

OBJECTIVE: To investigate the possible interference with acute hepatitis B virus infection by co-infection with hepatitis C virus.
DESIGN: Analysis of stored sera collected for transfusion transmitted viruses study in 1970s.
SETTING: Four major medical centres in the United States. PATIENTS: 12 recipients of blood infected with hepatitis B virus. MAIN OUTCOME MEASURES: In 1970s, presence of antibodies in hepatitis B virus and raised serum alanine aminotransferase concentration; detection of antibodies to hepatitis C virus with new enzyme linked immunoassays.
RESULTS: Five of the 12 patients were coinfected with hepatitis C virus. Hepatitis B surface antigen was first detected at day 59 in patients infected with hepatitis B virus alone and at day 97 in those coinfected with hepatitis C virus (p = 0.01); median durations of antigenaemia were 83 and 21 days respectively (p = 0.05), and the antigen concentration was lower in the coinfected patients. Alanine aminotransferase patterns were uniphasic when hepatitis B virus infection occurred alone (range 479-2465 IU/l) and biphasic in patients with combined acute infection (no value > 380 IU/l; p = 0.0025). Four coinfected recipients developed chronic hepatitis C virus infection. The fifth patient was followed for only four months.
CONCLUSIONS: Acute coinfection with hepatitis C virus and hepatitis B virus inhibits hepatitis B virus infection in humans, and onset of hepatitis B may reduce the severity of hepatitis C virus infection but not frequency of chronicity. Alanine aminotransferase concentration showed a biphasic pattern in dual infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251805      PMCID: PMC1679121          DOI: 10.1136/bmj.307.6912.1095

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  12 in total

1.  Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions.

Authors:  L Mimms; D Vallari; L Ducharme; P Holland; I K Kuramoto; J Zeldis
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

2.  Non-A, non-B hepatitis and antibody to hepatitis C virus.

Authors:  J W Mosley; R D Aach; F B Hollinger; C E Stevens; L H Barbosa; G J Nemo; P V Holland; W H Bancroft; H J Zimmerman; G Kuo
Journal:  JAMA       Date:  1990-01-05       Impact factor: 56.272

3.  Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice.

Authors:  P N Gilles; G Fey; F V Chisari
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study.

Authors:  C E Stevens; R D Aach; F B Hollinger; J W Mosley; W Szmuness; R Kahn; J Werch; V Edwards
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

5.  Differential diagnosis of acute viral hepatitis using rapid, fully automated immunoassays.

Authors:  K Eble; J Clemens; C Krenc; M Rynning; J Stojak; J Stuckmann; P Hutten; L Nelson; L DuCharme; S Hojvat
Journal:  J Med Virol       Date:  1991-03       Impact factor: 2.327

6.  Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays.

Authors:  R D Aach; C E Stevens; F B Hollinger; J W Mosley; D A Peterson; P E Taylor; R G Johnson; L H Barbosa; G J Nemo
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

7.  Serological markers of posttransfusion hepatitis C viral infection.

Authors:  D S Vallari; B W Jett; H J Alter; L T Mimms; R Holzman; J W Shih
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

8.  Non-B hepatitis in Japanese recipients of blood transfusions: clinical and serologic studies after the introduction of laboratory screening of donor blood for hepatitis B surface antigen.

Authors:  A Tateda; K Kikuchi; Y Numazaki; R Shirachi; N Ishida
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

9.  Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay.

Authors:  J Bukh; R H Purcell; R H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  Interference between non-A, non-B and hepatitis B virus infection in chimpanzees.

Authors:  B Brotman; A M Prince; T Huima; L Richardson; M C van den Ende; U Pfeifer
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

View more
  20 in total

Review 1.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 2.  MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

Authors:  Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu
Journal:  World J Hepatol       Date:  2015-03-27

3.  The occurrence of hepatitis B and C viruses in Pakistani patients with chronic liver disease and hepatocellular carcinoma.

Authors:  C Y Tong; R Khan; N J Beeching; W U Tariq; C A Hart; N Ahmad; I A Malik
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

4.  Concurrent infection with hepatitis B and C viruses.

Authors:  W L Irving; G Dolan
Journal:  BMJ       Date:  1994-01-15

5.  Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony.

Authors:  Shailaja Jamma; Ghazi Hussain; Daryl T-Y Lau
Journal:  Curr Hepat Rep       Date:  2010

Review 6.  New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.

Authors:  Mary C Kuhns; Michael P Busch
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.

Authors:  Jo Anne Chiavetta; Michael Escobar; Alice Newman; Yaohua He; Pete Driezen; Shelley Deeks; Devon E Hone; Sheila F O'Brien; Graham Sher
Journal:  CMAJ       Date:  2003-10-14       Impact factor: 8.262

8.  Hepatitis C comorbidities affecting the course and response to therapy.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 9.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

10.  Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.

Authors:  S D Ryder; W L Irving; D A Jones; K R Neal; J C Underwood
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.